Prostatic neoplasms: Clinical and biological aspects, histopathologic patterns;Cancer de la prostate: Les aspects cliniques, biologiques et histopathologiques utiles au radiologue

Journal de Radiologie

Volumn 87, Issue 2 C2, 2006, Pages 189-198

  Puech, P ^a   Villers, A ^a   Mouton, D ^a   Leroy, X ^a   Lemaitre L ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Prostate MR; Prostate neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; CONTRAST MEDIUM;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TUMOR VOLUME; ADULT; AGE; AGED; BIOPSY; BLOOD; CASE REPORT; COMPARATIVE STUDY; MALE; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROSTATE; PROSTATE TUMOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 33645581977     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(06)73993-2     Document Type: Article

References (37)

1. Brutel C. OL. Projections pour la France, ses régions et ses départements à l'horizon 2030. Données sociales, Insee 2002.
2. Lunenfeld B. The ageing male: demographics and challenges. World J Urol 2002;20:11-6.
3. Villers A SM, Culine S. Épidémiologie et dépistage du cancer de la prostate. Oncologie 2004;6.
4. Villers A, Rebillard X, Soulie M et al. Prostate cancer screening. Prog Urol 2003;13:209-14.
5. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
6. Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000;163:119-26.
7. Erbersdobler A, Huhle S, Palisaar J et al. Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone. Prostate Cancer Prostatic Dis 2002;5:279-84.
8. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989;141:1093-4.
9. McNeal JE, Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate 2001;49:48-57.
10. Villers A, McNeal JE, Redwine EA, Freiha FS, Stamey TA. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 1989;142:763-8.
11. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 1990;14:240-7.
12. Cruz M, Tsuda K, Narumi Y et al. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol 2002;12:357-65.
13. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med 2005;53:249-55.
14. Padhani AR, Gapinski CJ, Macvicar DA et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109.
15. Husband JE, Padhani AR, MacVicar AD, Revell P. Magnetic resonance imaging of prostate cancer: comparison of image quality using endorectal and pelvic phased array coils. Clin Radiol 1998; 53:673-81.
16. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 2004;233:709-15.
17. Pucar D, Shukla-Dave A, Hricak H et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236:545-53.
18. Roy C. Exploration de l'appareil urinaire en IRM : développements actuels et perspectives futures. J Radiol 2004;85:171-83.
19. Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS. Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 1990;143:1166-72.
20. Villers AA, McNeal JE, Redwine EA, Freiha FS, Stamey TA. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol 1990; 143:1183-7.
21. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
22. Ponchietti R, Di Loro F, Fanfani A, Amorosi A. Estimation of prostate cancer volume by endorectal coil magnetic resonance imaging vs. pathologic volume. Eur Urol 1999;35:32-5.
23. Larson BT, Collins JM, Huidobro C, Corica A, Vallejo S, Bostwick DG. Gadolinium-enhanced MRI in the evaluation of minimally invasive treatments of the prostate: correlation with histopathologic findings. Urology 2003;62:900-4.
24. Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics 2004;24 Suppl 1:S167-80.
25. Polo A, Cattani F, Vavassori A et al. MR and CT image fusion for postimplant analysis in permanent prostate seed implants. Int J Radiat Oncol Biol Phys 2004;60:1572-9.
26. Van Gellekom MP, Moerland MA, Van Vulpen M, Wijrdeman HK, Battermann JJ. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys 2005;63:772-80.
27. D'Amico A, Cormack R, Kumar S, Tempany CM. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. J Endourol 2000;14:367-70.
28. Rouvière O, Lyonnet D, Raudrant A et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001;40:265-74.
29. Kundu S RK, Antenor JA, Catalona WJ, Nadler RB. Age-specific risk of prostate cancer if PSA is between the median value and commonly used biopsy thresholds. AUA 2005;953.
30. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001;58:411-6.
31. Stamey TA, Sozen TS, Yemoto CM, McNeal JE. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 1998;159:2009-12.
32. Augustin H, Erbersdobler A, Graefen M et al. Differences in biopsy features between prostate cancers located in the transition and peripheral zone. BJU Int 2003;91:477-81.
33. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 1992;23:258-66.
34. Villers A, Stamey TA, Yemoto C, Rischmann P, McNeal JE. Modified extra fascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers <2cm. Eur Urol 2000;38:64-73.
35. Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000;163:1155-60.
36. Augustin H, Hammerer PG, Blonski J et al. Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? Urology 2003;62:79-85.
37. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol 2000;164:1596-600.